SAN DIEGO, Sept. 16, 2020 /PRNewswire/ — Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-phase biopharmaceutical firm dedicated to using proprietary gene engineering system technologies to generate future
SAN DIEGO, Sept. 16, 2020 /PRNewswire/ — Poseida Therapeutics, Inc., (Nasdaq: PSTX), a clinical-phase biopharmaceutical firm dedicated to using proprietary gene engineering system technologies to generate future